Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: Insights from the NeoAMR network

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3105300 53 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: Insights from the NeoAMR network
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objective To gain an understanding of the variation in available resources and clinical practices between neonatal units (NNUs) in the low-income and middle-income country (LMIC) setting to inform the design of an observational study on the burden of unit-level antimicrobial resistance (AMR). Design A web-based survey using a REDCap database was circulated to NNUs participating in the Neonatal AMR research network. The survey included questions about NNU funding structure, size, admission rates, access to supportive therapies, empirical antimicrobial guidelines and period prevalence of neonatal blood culture isolates and their resistance patterns. Setting 39 NNUs from 12 countries. Patients Any neonate admitted to one of the participating NNUs. Interventions This was an observational cohort study. Results The number of live births per unit ranged from 513 to 27 700 over the 12-month study period, with the number of neonatal cots ranging from 12 to 110. The proportion of preterm admissions <32 weeks ranged from 0% to 19%, and the majority of units (26/39, 66%) use Essential Medicines List 'Access' antimicrobials as their first-line treatment in neonatal sepsis. Cephalosporin resistance rates in Gram-negative isolates ranged from 26% to 84%, and carbapenem resistance rates ranged from 0% to 81%. Glycopeptide resistance rates among Gram-positive isolates ranged from 0% to 45%. Conclusion AMR is already a significant issue in NNUs worldwide. The apparent burden of AMR in a given NNU in the LMIC setting can be influenced by a range of factors which will vary substantially between NNUs. These variations must be considered when designing interventions to improve neonatal mortality globally. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Έτος δημοσίευσης:
2020
Συγγραφείς:
Li, G.
Bielicki, J.A.
Ahmed, A.S.M.N.U.
Islam, M.S.
Berezin, E.N.
Gallacci, C.B.
Guinsburg, R.
Da Silva Figueiredo, C.E.
Santarone Vieira, R.
Silva, A.R.
Teixeira, C.
Turner, P.
Nhan, L.
Orrego, J.
Pérez, P.M.
Qi, L.
Papaevangelou, V.
Triantafyllidou, P.
Iosifidis, E.
Roilides, E.
Sarafidis, K.
Jinka, D.R.
Nayakanti, R.R.
Kumar, P.
Gautam, V.
Prakash, V.
Seeralar, A.
Murki, S.
Kandraju, H.
Singh, S.
Kumar, A.
Lewis, L.
Pukayastha, J.
Nangia, S.
Yogesha, K.N.
Chaurasia, S.
Chellani, H.
Obaro, S.
Dramowski, A.
Bekker, A.
Whitelaw, A.
Thomas, R.
Velaphi, S.C.
Ballot, D.E.
Nana, T.
Reubenson, G.
Fredericks, J.
Anugulruengkitt, S.
Sirisub, A.
Wong, P.
Lochindarat, S.
Boonkasidecha, S.
Preedisripipat, K.
Cressey, T.R.
Paopongsawan, P.
Lumbiganon, P.
Pongpanut, D.
Sukrakanchana, P.-O.
Musoke, P.
Olson, L.
Larsson, M.
Heath, P.T.
Sharland, M.
Περιοδικό:
Archives of Disease in Childhood
Εκδότης:
BMJ Publishing Group
Τόμος:
105
Αριθμός / τεύχος:
1
Σελίδες:
26-31
Λέξεις-κλειδιά:
antiinfective agent; carbapenem; cephalosporin; polypeptide antibiotic agent, antibiotic resistance; antibiotic therapy; Article; artificial ventilation; blood culture; carbapenem resistance; cephalosporin resistance; clinical decision making; clinical feature; clinical practice; cohort analysis; data base; Gram negative bacterium; Gram positive bacterium; health care access; human; intubation; laboratory test; low income country; major clinical study; middle income country; neonatal intensive care unit; newborn; newborn mortality; newborn sepsis; noninvasive ventilation; observational study; prevalence; priority journal; total parenteral nutrition
Επίσημο URL (Εκδότης):
DOI:
10.1136/archdischild-2019-316816
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.